These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 26071630)
21. iRGD-mediated core-shell nanoparticles loading carmustine and O Liu C; Yao S; Li X; Wang F; Jiang Y J Drug Target; 2017 Mar; 25(3):235-246. PubMed ID: 27646474 [TBL] [Abstract][Full Text] [Related]
22. Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis. Tempfer CB; Hilal Z; Dogan A; Petersen M; Rezniczek GA Eur J Surg Oncol; 2018 Jul; 44(7):1112-1117. PubMed ID: 29753612 [TBL] [Abstract][Full Text] [Related]
24. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823 [TBL] [Abstract][Full Text] [Related]
25. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma. Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248 [TBL] [Abstract][Full Text] [Related]
26. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer. Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252 [TBL] [Abstract][Full Text] [Related]
27. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology. Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J Arch Gynecol Obstet; 2018 Apr; 297(4):837-846. PubMed ID: 29356953 [TBL] [Abstract][Full Text] [Related]
28. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Franko J; Ibrahim Z; Gusani NJ; Holtzman MP; Bartlett DL; Zeh HJ Cancer; 2010 Aug; 116(16):3756-62. PubMed ID: 20564081 [TBL] [Abstract][Full Text] [Related]
29. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation. Hu C; Huang Y; Chen Y Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418 [TBL] [Abstract][Full Text] [Related]
30. De novo design of a tumor-penetrating peptide. Alberici L; Roth L; Sugahara KN; Agemy L; Kotamraju VR; Teesalu T; Bordignon C; Traversari C; Rizzardi GP; Ruoslahti E Cancer Res; 2013 Jan; 73(2):804-12. PubMed ID: 23151901 [TBL] [Abstract][Full Text] [Related]
31. Pressurized Intraperitoneal Aerosol Chemotherapy, a Palliative Treatment Approach for Patients With Peritoneal Carcinomatosis: Description of Method and Systematic Review of Literature. Winkler CS; Sandhu J; Pettke E; Merchea A; Fong Y; Kumara HMCS; Whelan RL Dis Colon Rectum; 2020 Feb; 63(2):242-255. PubMed ID: 31914116 [TBL] [Abstract][Full Text] [Related]
32. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Girard OM; Hanahan D; Mattrey RF; Ruoslahti E Cancer Cell; 2009 Dec; 16(6):510-20. PubMed ID: 19962669 [TBL] [Abstract][Full Text] [Related]
33. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer. Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161 [TBL] [Abstract][Full Text] [Related]
34. Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei. Bjersand K; Mahteme H; Sundström Poromaa I; Andréasson H; Graf W; Larsson R; Nygren P Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S810-6. PubMed ID: 26193962 [TBL] [Abstract][Full Text] [Related]
35. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice. Hu C; Chen X; Huang Y; Chen Y Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179 [TBL] [Abstract][Full Text] [Related]
36. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Lo JH; Hao L; Muzumdar MD; Raghavan S; Kwon EJ; Pulver EM; Hsu F; Aguirre AJ; Wolpin BM; Fuchs CS; Hahn WC; Jacks T; Bhatia SN Mol Cancer Ther; 2018 Nov; 17(11):2377-2388. PubMed ID: 30097486 [TBL] [Abstract][Full Text] [Related]
37. Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years' experience of a new centre for peritoneal surface malignancies. Bretcha-Boix P; Farré-Alegre J; Sureda M; Dussan C; Pérez Ruixo JJ; Brugarolas Masllorens A Clin Transl Oncol; 2010 Jun; 12(6):437-42. PubMed ID: 20534399 [TBL] [Abstract][Full Text] [Related]
38. A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report. Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Nishikawa T; Tanaka J; Tanaka T; Kiyomatsu T; Kawai K; Hata K; Nozawa H; Kazama S; Ishihara S; Sunami E; Watanabe T J Med Case Rep; 2016 Jan; 10():14. PubMed ID: 26786355 [TBL] [Abstract][Full Text] [Related]
39. Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. Colombo PE; Boustta M; Poujol S; Pinguet F; Rouanet P; Bressolle F; Vert M Eur J Pharm Sci; 2007 May; 31(1):43-52. PubMed ID: 17383164 [TBL] [Abstract][Full Text] [Related]
40. iRGD as a tumor‑penetrating peptide for cancer therapy (Review). Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]